NCT06211114 is a Phase 2 clinical trial of PD-(L)1 inhibitor in Collecting Duct Carcinoma, sponsored by Peking University Cancer Hospital & Institute.

Who is sponsoring NCT06211114?

NCT06211114 is sponsored by Peking University Cancer Hospital & Institute.

What drugs are being tested in NCT06211114?

Interventions in NCT06211114: PD-(L)1 inhibitor, Axitinib.

What condition does NCT06211114 study?

NCT06211114 studies Collecting Duct Carcinoma.

Is NCT06211114 still recruiting?

NCT06211114 is currently recruiting now. Last updated 21 November 2024.

Last reviewed 2024-11-21 · How we verify

NCT06211114

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate the Efficacy and Safety of Immune Checkpoint Inhibitors in Combination With Axitinib in Previously Treated Advanced Collecting Duct Carcinoma

Recruiting now Phase 2 Last updated 21 November 2024

What this trial tests

Phase 2 trial testing PD-(L)1 inhibitor in Collecting Duct Carcinoma in 30 participants. Currently enrolling.

Timeline

9 February 2024

Primary endpoint
1 February 2026

1 February 2027

Quick facts

Lead sponsor	Peking University Cancer Hospital & Institute
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	9 February 2024
Primary completion	1 February 2026
Estimated completion	1 February 2027
Sites	2 locations across China

Drugs / interventions tested

PD-(L)1 inhibitor
Axitinib — full drug profile →

Conditions studied

Collecting Duct Carcinoma — all drugs for Collecting Duct Carcinoma →

Sponsor

Peking University Cancer Hospital & Institute

Who can join

Adults 18 to 80, any sex, with Collecting Duct Carcinoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

ORR assessed by investigators per RECIST 1.1
Time frame: Up to approximately 2 years
The treatment effect of with ICI plus axitinib will be assessed using RECIST 1.1 to determine tumor response.

Sponsor's own description

This is a phase II trial to evaluate the efficacy and safety of immune checkpoint inhibitors in combination with axitinib for previously treated advanced collecting duct carcinoma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Recent progress in non-clear cell renal cell carcinoma: biology and therapeutic strategies.
Yildirim A, Moses MW, Gerke M, Jani Y, et al · · 2025 · cited 2× · PMID 40535735 · DOI 10.1177/17588359251345722

Verify or expand the search:

Other recruiting trials for Collecting Duct Carcinoma

Currently open trials in the same condition.

NCT04071223 — Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advance · Phase 2 · active not recruiting
NCT03866382 — Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabo · Phase 2 · recruiting

Other Peking University Cancer Hospital & Institute trials

Trials by the same sponsor.

NCT07527806 — Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Im · Phase 2 · not yet recruiting
NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
NCT07417241 — SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study · Phase 2 · not yet recruiting
NCT07470203 — Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer · not yet recruiting
NCT07394192 — Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-I · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06211114 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University Cancer Hospital & Institute
Last refreshed: 21 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06211114.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing